お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:緑内障:競合情勢 (2026年)
市場調査レポート
商品コード
778085

緑内障:競合情勢 (2026年)

Glaucoma: Competitive Landscape to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 48 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
緑内障:競合情勢 (2026年)
出版日: 2018年12月21日
発行: GlobalData
ページ情報: 英文 48 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の緑内障市場について調査し、パイプライン (地域内訳、有望な後期段階製品、分子タイプ別の初期段階パイプライン)、治験 (フェーズごとの治験内訳、主要な産業・非産業スポンサー、登録分析) 、および商業情勢 (主な上市製品、現在・将来の企業)、ならびに競合環境について分析しており、今後10年間にわたって緑内障市場の成長を促進する新規医薬品承認の予測などを提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 パイプライン評価

  • パイプライン概要
  • パイプライン分析:地域/国別
  • パイプライン分析:分子タイプ・ターゲット別
  • 医薬品見直しの指定
  • 臨床開発における製品

第5章 治験評価

  • 治験の概要
  • 緑内障における治験の主要スポンサー
  • 試験の内訳:地域別
  • 治療領域の展望
  • 登録数の分析

第6章 商業評価

  • 主な上市製品
  • 現在 & 将来の企業

第7章 競合情勢の分析

  • イベント分類の概要
  • 米国
  • EU5ヶ国
  • 日本・中国

第8章 付録

目次
Product Code: GDHC022CL

With no new classes of drugs having been developed for the treatment of glaucoma in the last twenty years, the focus of pharmaceutical companies has begun to shift towards the development of glaucoma drugs with novel mechanisms of action (MOAs), and this trend is expected to continue to 2026. The launch of 11 new therapies will drive growth in the glaucoma space, provide more options for patients, and stimulate further competition.

The glaucoma pipeline features 120 drugs across all stages of development, with more than two-thirds of the pipeline drugs being developed in early stage. Small molecules are the focus of drug developers as these constitute more than 68% of the total glaucoma pipeline drugs. According to latest report: 'Glaucoma: Competitive Landscape to 2026' 11 late-stage drug products will launch in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China) during, or shortly after, the forecast period from 2016 to 2026.

Glaucoma is an established indication, with large numbers of treatments that have become available over the years, and as a result the disease is generally associated with low levels of unmet needs. However, some unmet need does remain in this disease area, with most of these generally considered to be for greater patient compliance.

The importance of a greater compliance in glaucoma is reflected in the late-stage pipeline, which contains several products developed to help meet this unmet need. In particular, there are two SR implants, Ocular Therapeutix's OTX-TP and Allergan's Bimatoprost SR, which will provide a sustained release of drugs directly into the eye, and avoid potential issues of non-compliance associated with topical drugs. These two products, when they will be launched, are expected to have a significant impact on the glaucoma market.

The glaucoma market is highly competitive, heavily genericized and dominated by PGA drugs, particularly by generic latanoprost, which captures the largest patient share of any glaucoma drug throughout the 8MM. However, ample opportunity exists for new treatment options to impact the market, as highlighted by a healthy late-stage clinical pipeline.

Even though the glaucoma market is crowded and increasingly genericized, there are opportunities for products that are able to help address existing unmet needs. The first SR implants for glaucoma are set to launch in 2020, and are expected to improve compliance and convenience of treatment in glaucoma patients. However, all developmental implants currently use a PGA as the active component, meaning there is opportunity for further implants that contain other therapeutic classes as the active ingredient, or even an FDC of multiple drugs.

The report "Glaucoma: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. It expects new drug approvals to drive Glaucoma market growth over the next decade (2016-2026).

Scope

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape: Analysis-key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4

2. Executive Summary 5

  • 2.2 Key Findings 6
  • 2.2 Key Events 7

3. Introduction 8

  • 3.1 Report Scope 9-10
  • 3.2 Disease Overview and Epidemiology 11-13

4. Pipeline Assessment 14

  • 4.1 Pipeline Overview 15-16
  • 4.2 Pipeline Breakdown by Region/Country 17
  • 4.3 Pipeline Breakdown by Molecule Type and Target 18
  • 4.4 Drug Review Designations 19
  • 4.5 Products in Clinical Development 20-21

5. Clinical Trial Assessment 22

  • 5.1 Clinical Trials Overview 23
  • 5.2 Top Sponsors of Clinical Trials in Glaucoma 24-25
  • 5.3 Trial Breakdown by Region 26
  • 5.4 Therapy Area Perspective 27
  • 5.5 Enrollment Analytics 28-30

6 Commercial Assessment 31

  • 6.1 Leading Marketed Products 32
  • 6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

  • 7.1 Events Classification Overview 35
  • 7.2 US 36
  • 7.3 5EU 37
  • 7.4 Japan and China 38

8 Appendix 39

  • 8.1 Sources 40
  • 8.2 Methodology 41
  • 8.3 Key Events Included in the Analysis 42
  • 8.4 About the Authors 43-45
  • 8.5 About GlobalData 46
  • 8.6 Disclaimer 48
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.